Severity
Critical
FDA Devices recall · Reported May 18, 2022
Firm distributed tests which have not been cleared or authorized for marketing or distribution in the United States.
Woodside Acquisitions Inc. recalled Joysbio SARS-CoV-2 Antigen Rapid Test Kit (Colloidal Gold); COVID 19 Test - a critical-severity action.
Joysbio SARS-CoV-2 Antigen Rapid Test Kit (Colloidal Gold); COVID 19 Test was recalled by Woodside Acquisitions Inc. in May 18, 2022. Reason: Firm distributed tests which have not been cleared or authorized for marketing or distribution in the United …. Check the official notice for the remedy. Verify recall #Z-1045-2022 with the FDA Devices before acting.
The recall
Woodside Acquisitions Inc. issued this critical-severity FDA Devices recall-Firm distributed tests which have not been cleared or authorized for marketing or distribution in the United ….
Sourced from official FDA Devices enforcement records. Verify recall #Z-1045-2022 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Devices action (record #Z-1045-2022) was formally reported on May 18, 2022, with the manufacturer initiating the action on April 9, 2022. It is classified under Critical severity (Class I), with a current status of Ongoing. Woodside Acquisitions Inc. is listed as the recalling firm, operating out of tyrone, PA. Federal records list the affected scope as 17,000 units.
The documented reason for this recall is: Firm distributed tests which have not been cleared or authorized for marketing or distribution in the United States. Distribution data in the federal record shows the product reached: US distributions to states of: AL and GA.. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 3 from FDA Devices - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 40,322 medical devices recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified high severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Critical
Affected scope
17,000 units
Related Recalls
6
3 from same agency
Joysbio SARS-CoV-2 Antigen Rapid Test Kit (Colloidal Gold); COVID 19 Test
Firm distributed tests which have not been cleared or authorized for marketing or distribution in the United States.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Critical (Class I) |
| Status | Ongoing |
| Recall number | Z-1045-2022 |
| Date reported | May 18, 2022 |
| Date initiated | April 9, 2022 |
| Recalling firm | Woodside Acquisitions Inc. |
| Firm location | tyrone, PA |
| Affected scope | 17,000 units |
| Distribution | US distributions to states of: AL and GA. |
Profile values are sourced directly from the official FDA Devices enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Devices record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
· 2026-07-02
· 2026-06-25
· 2026-06-18
GE Medical Systems Information Technologies Inc · 2026-06-03
Medline Industries, LP · 2026-06-03
Compare this recall with Rowenta Recalls Cordless Vacuum Cleaners Due to Risk of Ser… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Devices, reported May 18, 2022. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.